Stockscreener 앱 받기
189.94
2.34%
4.32
시간 외 거래:
189.20
-0.74
-0.39%
Abbvie Inc 주식(ABBV)의 최신 뉴스
AbbVie (NYSE:ABBV) migraine drug update boosts biotech pipeline strength S&P 500 - Kalkine Media
AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant - Yahoo Finance
AbbVie's migraine drug meets main goal in head-to-head study with topiramate - Reuters
AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial - Benzinga
AbbVie’s atogepant achieves superiority in migraine prevention - The Pharma Letter
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - PharmaLive
AbbVie (ABBV) Sees Success with Migraine Drug Atogepant in Late-Stage Trial - GuruFocus
AbbVie Stock (ABBV) Dips: A Buying Opportunity for its 3.55% Dividend Yield? - Daily Chhattisgarh News
Hidradenitis Suppurativa Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte, CSL Behring - Barchart.com
AbbVie succeeds in late-stage migraine treatment trial (ABBV) - Seeking Alpha
AbbVie’s migraine drug meets main goal of late-stage study - 1470 & 100.3 WMBD
AbbVie (ABBV) Reports Positive Results from Migraine Study | ABBV Stock News - GuruFocus
AbbVie Reports Positive Topline Results From Phase 3 TEMPLE Study Of Atogepant For Migrane - Nasdaq
AbbVie Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - Investing News Network
Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com
AbbVie’s atogepant shows superior results in migraine prevention trial By Investing.com - Investing.com Canada
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention | ABBV St - GuruFocus
AbbVie's migraine drug meets main goal of late-stage study - TradingView
Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance
AbbVie’s $1.6 Billion Break Fee Sidesteps Capital Loss Limit (1) - news.bloombergtax.com
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - Investing News Network
AbbVie (ABBV) Faces Potential Challenges Amid U.S. Advertising P - GuruFocus
RFK Jr. plans crackdown on pharma ads in threat to AbbVie's $2 billion marketing strategy - Crain's Chicago Business
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes - Benzinga
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study - Nasdaq
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq
AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint - Yahoo Finance
AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow (NYSE:ABBV) - Seeking Alpha
AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics - MSN
AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C - Insider Monkey
AbbVie says blood cancer drug fails late-stage trial - Reuters
Sector Update: Health Care Stocks Retreat Late Afternoon - MarketScreener
Sector Update: Health Care - marketscreener.com
AbbVie cancer drug misses the mark in trial for new use - Crain's Chicago Business
AbbVie (ABBV) and Genentech Report Phase III Study Results for Venclexta | ABBV Stock News - GuruFocus
AbbVie (ABBV) Faces Setback in VERONA Study for Venclexta | ABBV Stock News - GuruFocus
AbbVie stock dips after cancer drug trial setback - TradingView
AbbVie (ABBV) Faces Setback with Leukemia Drug Trial - GuruFocus
AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax - Seeking Alpha
AbbVie: trial fails in myelodysplastic syndrome - MarketScreener
AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment - MarketScreener
Here's Why AbbVie (ABBV) is a Strong Value Stock - Yahoo Finance
AbbVie Says Myelodysplastic Syndrome Phase 3 Trial Failed to Meet Primary Endpoint - marketscreener.com
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Highe - GuruFocus
AbbVie (ABBV) Phase 3 Trial on Myelodysplastic Syndrome Falls Short | ABBV Stock News - GuruFocus
AbbVie’s venetoclax fails in phase 3 trial for MDS treatment By Investing.com - Investing.com Canada
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery - Yahoo Finance
AbbVie Provides Update On VERONA Trial For Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - marketscreener.com
AbbVie's Phase 3 VERONA Trial Falls Short: Key Results for Venetoclax MDS Treatment Revealed - Stock Titan
AbbVie: Margin Clarity, Dividend Durability Awaited (NYSE:ABBV) - Seeking Alpha
AbbVie, Chicago Cubs step up to plate to hit a cancer research grand slam - Medical Marketing and Media
AbbVie Moves From Blockbuster Loss To Market Domination (NYSE:ABBV) - Seeking Alpha
AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth (NYSE:ABBV) - Seeking Alpha
AbbVie's Post-Humira Strategy Is Paying Off For Investors (NYSE:ABBV) - Seeking Alpha
AbbVie Unethical Marketing Scandal: Department of Pharmaceuticals Refuses to Name Doctors - Daily Chhattisgarh News
USFDA approves expanded indication for AbbVie Mavyret for Acute Hepatitis C Virus - Medical Dialogues
Pharma dept refuses to name 30 docs penalised for Paris, Monaco trip - The New Indian Express
AbbVie Sues Colo. Over State Discount Drug Law - Law360
Dividend Stock Portfolio For Retirement - Insider Monkey
AbbVie Secures FDA Approval to Expand Mavyret’s Label - MSN
FDA approves label expansion of AbbVie hepatitis C therapy - Yahoo
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - MSN
Kalkine: Can FDA Approval Reshape AbbVie’s Role In S&P 500 - Kalkine Media
AbbVie (NYSE:ABBV) Achieves FDA Approval for MAVYRET Label Expansion to Treat Pediatric Hepatitis C - Yahoo Finance
1.17%
자본화:
|
볼륨(24시간):